BioBusiness

Will Exelixis's novel approach pay off in the current economic climate?

Frankie Trull wants to sell your company to Congress.

How companies plan to make money (really) off of embryonic stem cells.

New organizations want to help you succeed in biotech - for free.

FDA scientists are increasingly unhappy, due to in-house pressures and public criticism. How can the agency restore what it once was?

Immune Control CEO Stephen Roth is banking on a controversial hypothesis and is fashioning ways to block a neurotransmitter to fight autoimmune disease.

The legislation is credited with building biotech and spawning hundreds of drugs for rare diseases. So why do some analysts hesitate to call it a success?

AstraZeneca's Karen Gotting-Smith is using a newly-created position to tackle some old problems.

John Prakash was once denied a job because of the way he looked. Now he spends his career talking about why diversity is crucial to drug development.

At Merck, Eric Schadt takes an iconoclastic approach to drug discovery - and dressing.

Can a company harness stem cells to treat injured horses?

At Procter & Gamble, Thomas Dawson has led the charge to put more biology in every bottle of shampoo.

Coming up with an entirely new approach to cancer therapy can be a headache, as Micromet's Christian Itin has learned.

Millennium Pharmaceuticals' Joe Bolen has kept scientists' morale high through wrenching changes.

At Taiwan's TCM Biotech, Ya-Chun Wang converts ancient Chinese secrets into modern pharmaceuticals - and gets the FDA to pay attention.

Helicos' Bill Efcavitch is confident that he can produce a machine that can sequence a genome for $1,000 in ten days. It hasn't been an easy road.

How one company helped seed San Diego's industry.

How Cubist's Jeff Alder turned a devastating Phase III failure into an approval.

Some executives would have left a company after being demoted. Graham Allaway didn't do that at the HIV therapeutics company Panacos, and it's better because of it.

Norbert Riedel's focus on science has helped pull Baxter out of a slump.